CN1035823A - 1，4-二取代哌啶基化合物 - Google Patents

1，4-二取代哌啶基化合物 Download PDF

Info

Publication number
CN1035823A
CN1035823A CN89100339A CN89100339A CN1035823A CN 1035823 A CN1035823 A CN 1035823A CN 89100339 A CN89100339 A CN 89100339A CN 89100339 A CN89100339 A CN 89100339A CN 1035823 A CN1035823 A CN 1035823A
Authority
CN
China
Prior art keywords
compound
fluorophenyl
halogen
formula
accordance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN89100339A
Other languages
English (en)
Chinese (zh)
Inventor
阿尔伯特·A·卡尔
弗朗西斯·P·米勒
萨多斯·R·耐多萨克
斯蒂芬·M·索伦森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis UK Holdings Ltd
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Ltd filed Critical Merrell Dow Pharmaceuticals Ltd
Publication of CN1035823A publication Critical patent/CN1035823A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN89100339A 1988-01-21 1989-01-21 1，4-二取代哌啶基化合物 Pending CN1035823A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14664788A 1988-01-21 1988-01-21
US146,647 1988-01-21
US07/279,900 US5064838A (en) 1988-01-21 1988-12-07 1,4-disubstituted-piperidinyl compounds as pain relievers
US279,900 1988-12-07

Publications (1)

Publication Number Publication Date
CN1035823A true CN1035823A (zh) 1989-09-27

Family

ID=48782796

Family Applications (1)

Application Number Title Priority Date Filing Date
CN89100339A Pending CN1035823A (zh) 1988-01-21 1989-01-21 1，4-二取代哌啶基化合物

Country Status (18)

Country Link
US (1) US5064838A (enExample)
EP (1) EP0325268B1 (enExample)
JP (1) JP2967990B2 (enExample)
KR (1) KR0131377B1 (enExample)
CN (1) CN1035823A (enExample)
AR (2) AR247385A1 (enExample)
AT (1) ATE90077T1 (enExample)
AU (1) AU615713B2 (enExample)
CA (1) CA1330087C (enExample)
DE (1) DE68906801T2 (enExample)
DK (1) DK26389A (enExample)
ES (1) ES2058346T3 (enExample)
FI (1) FI90534C (enExample)
HU (2) HU202494B (enExample)
NO (1) NO174505B (enExample)
NZ (1) NZ227643A (enExample)
PH (1) PH27115A (enExample)
PT (1) PT89497B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR910006138B1 (ko) * 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
US5292752A (en) * 1989-12-21 1994-03-08 Merrell Dow Pharmaceuticals Inc. Antithrombotic compounds
NZ236501A (en) * 1989-12-21 1992-12-23 Merrell Dow Pharma Piperidine derivatives and antithrombotic compositions
AU652759B2 (en) * 1990-06-01 1994-09-08 Aventisub Ii Inc. (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol
DK0532629T3 (da) * 1990-06-07 1996-11-25 Merrell Pharma Inc 1-Piperidinyl-alkanoylarylsulfonamid-derivater
FR2672286B1 (fr) * 1991-01-31 1994-11-18 Synthelabo Derives de 1-(4-chlorophenyl)-2-[4-(phenylmethyl)piperidin-1-yl]ethanol, leur preparation et leur application en therapeutique.
WO1992020661A1 (en) * 1991-05-22 1992-11-26 Merck & Co., Inc. N, n-diacylpiperazines
FR2678269B1 (fr) * 1991-06-27 1995-01-13 Synthelabo Derives de 1-(4-chlorophenyl)-2-[4-(2-phenylethyl)piperidin-1-yl]ethanol, leur application et leur preparation en therapeutique.
US6048859A (en) * 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5637699A (en) * 1992-06-29 1997-06-10 Merck & Co., Inc. Process for preparing morpholine tachykinin receptor antagonists
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US5387595A (en) * 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
FR2696741B1 (fr) * 1992-10-12 1994-11-25 Synthelabo Dérivés de 1-(4-chlorophényl)-2-[4-[(4-fluorophényl)méthyl]piperidin-1-yl] éthanol, leur préparation et leur application en thérapeutique.
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
US5348955A (en) * 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
US5610165A (en) * 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
EP0796619A1 (en) 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
ATE285403T1 (de) 1997-10-31 2005-01-15 Daiichi Suntory Pharma Co Ltd Verfahren zur herstellung von n-((4- phenyl)methylphenyl)piperazinen
US6713627B2 (en) 1998-03-13 2004-03-30 Aventis Pharmaceuticals Inc. Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US20050261341A1 (en) * 1998-03-13 2005-11-24 Aventis Pharmaceuticals Inc. Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
US6277864B1 (en) 1998-08-28 2001-08-21 Aventis Pharmaceuticals Inc. Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders
US6939879B2 (en) * 1998-08-28 2005-09-06 Aventis Pharmaceuticals Inc. Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576810A (en) * 1968-06-20 1971-04-27 Robins Co Inc A H 1-substituted-3-(-4)-aroylpiperidines
GB1402889A (en) * 1973-02-03 1975-08-13 Ciba Geigy Ag Piperidine derivatives
FR2581993B1 (fr) * 1985-05-14 1988-03-18 Synthelabo Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique
KR910006138B1 (ko) * 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체

Also Published As

Publication number Publication date
ES2058346T3 (es) 1994-11-01
PH27115A (en) 1993-03-16
HU205073B (en) 1992-03-30
FI890245A7 (fi) 1989-07-22
DK26389A (da) 1989-07-22
AU2868789A (en) 1989-07-27
FI90534B (fi) 1993-11-15
HU202494B (en) 1991-03-28
JP2967990B2 (ja) 1999-10-25
HUT52050A (en) 1990-06-28
EP0325268B1 (en) 1993-06-02
PT89497B (pt) 1994-03-31
DK26389D0 (da) 1989-01-20
NZ227643A (en) 1991-01-29
AU615713B2 (en) 1991-10-10
FI890245A0 (fi) 1989-01-17
ATE90077T1 (de) 1993-06-15
HUT53871A (en) 1990-12-28
EP0325268A1 (en) 1989-07-26
NO890269D0 (no) 1989-01-20
AR247385A1 (es) 1994-12-29
PT89497A (pt) 1989-10-04
FI90534C (fi) 1994-02-25
DE68906801D1 (de) 1993-07-08
US5064838A (en) 1991-11-12
KR890011840A (ko) 1989-08-22
HU900238D0 (en) 1990-03-28
NO174505C (enExample) 1994-05-18
JPH01224360A (ja) 1989-09-07
AR244666A1 (es) 1993-11-30
NO890269L (no) 1989-07-24
KR0131377B1 (ko) 1998-04-17
DE68906801T2 (de) 1993-09-23
NO174505B (no) 1994-02-07
CA1330087C (en) 1994-06-07

Similar Documents

Publication Publication Date Title
CN1035823A (zh) 1，4-二取代哌啶基化合物
CN1217720A (zh) 苯并呋喃基衍生物及其应用
EP1682503A2 (fr) Derives de n-[phenyl(alkylpiperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
IE862802L (en) Crystalline paroxetine
EP0522915B1 (fr) Dérivés de pyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique
CN1092657C (zh) 一釜法合成2－噁唑烷酮衍生物
CN1108239A (zh) 杀虫(菌)剂及其中间体的制备方法
CN86107544A (zh) 黄酮衍生物的制备方法
JP4491135B2 (ja) ２−置換ピペリジン立体異性体を製造するための方法及び中間体
CN1268889A (zh) 新方法
CN88102422A (zh) 苯并氮杂草衍生物
CN1255496A (zh) 杂二环醇对映体在制备哌嗪衍生物中的用途
CN1063487A (zh) 苯氧基烷基羧酸衍生物及其制备方法
CN1019974C (zh) 1，4-二取代哌啶基化合物的制备方法
CN1183769A (zh) α-(取代的烷基苯基)-4-(羟基二苯基甲基)-1-哌啶丁醇衍生物,其制备和其用作抗组胺剂、抗变应性剂和支气管扩张药的用途
EP0699680B1 (fr) Dérivés d'oxazoloquinoleinone, leur préparation et leur application en thérapeutique
CN1337956A (zh) 新的吗啉代苯甲酰胺盐
CN1121383C (zh) 地尔硫䓬合成的废产物的再利用方法
EP0520882B1 (fr) Dérivés de 2-aminopyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique
CN1156448C (zh) 3－甲基芬太尼衍生物的光学异构体、合成及它们镇痛活性
CN1026586C (zh) 新的噻唑烷酮衍生物制备方法
CN101130520A (zh) 经非对映异构体盐的外消旋体拆分制备天然(-)-石杉碱甲和非天然(+)-石杉碱甲的新方法
WO2011040717A2 (en) Method for preparing intermediate of sitagliptin using chiral oxirane
CN1054882C (zh) 立体选择性制备杂二环醇对映体的酶促方法
CN1413976A (zh) 左旋沙丁胺醇制备新工艺

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication